Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma

Nature Genetics

Volumn 48, Issue 4, 2016, Pages 398-406

  Bonilla, Ximena ^a   Parmentier, Laurent ^b   King, Bryan ^c   Bezrukov, Fedor ^d,e   Kaya, Gürkan ^f   Zoete, Vincent ^g   Seplyarskiy, Vladimir B ^h,i,j   Sharpe, Hayley J ^k   McKee, Thomas ^f   Letourneau, Audrey ^a   Ribaux, Pascale G ^a   Popadin, Konstantin ^a   Basset Seguin, Nicole ^l   Chaabene, Rouaa Ben ^a   Santoni, Federico A ^a,f   Andrianova, Maria A ^h,i,j   Guipponi, Michel ^f   Garieri, Marco ^a   Verdan, Carole ^f   Grosdemange, Kerstin ^f   Sumara, Olga ^m   Eilers, Martin ^m   Aifantis, Iannis ^c   Michielin, Olivier ^g,n   De Sauvage, Frederic J ^k   Antonarakis, Stylianos E ^a,f,o   Nikolaev, Sergey I ^a,f   more..

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b Valais Hospital   (Switzerland)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e RIKEN BNL RESEARCH CENTER   (United States)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^h INSTITUTE FOR INFORMATION TRANSMISSION PROBLEMS   (Russian Federation)

ⁱ PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^j MOSCOW STATE UNIVERSITY   (Russian Federation)

^k GENENTECH INC   (United States)

^l SAINT LOUIS HOSPITAL   (France)

^m UNIVERSITY OF WÜRZBURG   (Germany)

ⁿ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^o Institute of Genetics and Genomics in Geneva (iGE3)   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SONIC HEDGEHOG PROTEIN; ANILIDE; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE; TRANSCRIPTOME; VISMODEGIB;

ARTICLE; BASAL CELL CARCINOMA; CANCER GROWTH; CONTROLLED STUDY; ERBB2 GENE; GENE; GENE MUTATION; GENETIC ANALYSIS; HRAS GENE; HUMAN; HUMAN TISSUE; KRAS GENE; LATS1 GENE; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MYCN GENE; NRAS GENE; PHENOTYPIC VARIATION; PIK3CA GENE; PPP6C GENE; PRIORITY JOURNAL; PTCH1 GENE; SKIN BASAL CELL CARCINOMA; SMO GENE; STK19 GENE; SUFU GENE; TP53 GENE; CARCINOGENESIS; CARCINOMA, BASAL CELL; DISEASE COURSE; DNA MUTATIONAL ANALYSIS; EXOME; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; HEK293 CELL LINE; MUTATION; PATHOLOGY; RADIATION RESPONSE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; CARCINOMA, BASAL CELL; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; EXOME; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HEK293 CELLS; HUMANS; MUTATION; PYRIDINES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TRANSCRIPTOME;

EID: 84960145215     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3525     Document Type: Article

References (87)

1. Iwasaki, J.K., Srivastava, D., Moy, R.L., Lin, H.J., & Kouba, D.J. The molecular genetics underlying basal cell carcinoma pathogenesis and links to targeted therapeutics. J. Am. Acad. Dermatol. 66, e167-e178 (2012
2. Youssef K.K., et al. Identification of the cell lineage at the origin of basal cell carcinoma. Nat. Cell Biol. 12, 299-305 (2010
3. Hahn H., et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85, 841-851 (1996
4. Reifenberger, J., et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br. J. Dermatol. 152, 43-51 (2005
5. Sharpe H.J., et al. Genomic analysis of Smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell 27, 327-341 (2015
6. Atwood S.X., et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell 27, 342-353 (2015
7. Smith M.J., et al. Germline mutations in SUFU cause Gorlin syndrome-Associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J. Clin. Oncol. 32, 4155-4161 (2014
8. Sweeney R.T., et al. Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat. Genet. 46, 722-725 (2014
9. Laurendeau I., et al. Gene expression profiling of the hedgehog signaling pathway in human meningiomas. Mol. Med. 16, 262-270 (2010
10. Brastianos P.K., et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat. Genet. 45, 285-289 (2013
11. Pomeroy S.L., et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415, 436-442 (2002
12. Clark, V.E., et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339, 1077-1080 (2013
13. Jayaraman, S.S., Rayhan, D.J., Hazany, S., & Kolodney, M.S. Mutational landscape of basal cell carcinomas by whole-exome sequencing. J. Invest. Dermatol. 134, 213-220 (2014
14. Basset-Seguin, N., et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 16, 729-736 (2015
15. Von Hoff D.D., et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361, 1164-1172 (2009
16. Sekulic A., et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N. Engl. J. Med. 366, 2171-2179 (2012
17. Dreno, B., Basset-Seguin, N., Caro, I., Yue, H., & Schadendorf, D. Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma. Oncologist 19, 790-796 (2014
18. Chang, A.L., & Oro, A.E. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch. Dermatol. 148, 1324-1325 (2012
19. Lawrence M.S., et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014
20. Hodis E., et al. A landscape of driver mutations in melanoma. Cell 150, 251-263 (2012
21. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161 1681-1696 (2015
22. Nikolaev S.I., et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat. Genet. 44, 133-139 (2012
23. Drobetsky, E.A., & Sage, E. UV-induced G:C-A:T transitions at the APRT locus of Chinese hamster ovary cells cluster at frequently damaged 5'-TCC-3' sequences. Mutat. Res. 289, 131-138 (1993
24. Marionnet, C., Benoit, A., Benhamou, S., Sarasin, A., & Stary, A. Characteristics of UV-induced mutation spectra in human XP-D/ERCC2 gene-mutated xeroderma pigmentosum and trichothiodystrophy cells. J. Mol. Biol. 252, 550-562 (1995
25. Alexandrov L.B., et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013
26. Hanawalt, P.C., Donahue, B.A., & Sweder, K.S. Repair and transcription. Collision or collusion? Curr. Biol. 4, 518-521 (1994
27. Besaratinia, A., Kim, S.I., Bates, S.E., & Pfeifer, G.P. Riboflavin activated by ultraviolet A1 irradiation induces oxidative DNA damage-mediated mutations inhibited by vitamin C. Proc. Natl. Acad. Sci. USA 104, 5953-5958 (2007
28. Brash, D.E. UV signature mutations. Photochem. Photobiol. 91, 15-26 (2015
29. Hu, J., Adar, S., Selby, C.P., Lieb, J.D., & Sancar, A. Genome-wide analysis of human global and transcription-coupled excision repair of UV damage at single-nucleotide resolution. Genes Dev. 29, 948-960 (2015
30. McGregor J.M., et al. Spectrum of p53 gene mutations suggests a possible role for ultraviolet radiation in the pathogenesis of advanced cutaneous lymphomas. J. Invest. Dermatol. 112, 317-321 (1999
31. da Silva Almeida A.C., et al. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. Nat. Genet. 47, 1465-1470 (2015
32. Strano S., et al. Mutant p53: an oncogenic transcription factor. Oncogene 26, 2212-2219 (2007
33. Kato, G.J., & Dang, C.V. Function of the c-Myc oncoprotein. FASEB J. 6, 3065-3072 (1992
34. Bahram, F., von der Lehr, N., Cetinkaya, C., & Larsson, L.G. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 95, 2104-2110 (2000
35. Welcker M., et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl. Acad. Sci. USA 101, 9085-9090 (2004
36. Freier K., et al. Recurrent NMYC copy number gain and high protein expression in basal cell carcinoma. Oncol. Rep. 15, 1141-1145 (2006
37. Stacey S.N., et al. New basal cell carcinoma susceptibility loci. Nat. Commun. 6, 6825 (2015
38. Knoepfler, P.S., & Kenney, A.M. Neural precursor cycling at sonic speed: N-Myc pedals, GSK-3 brakes. Cell Cycle 5, 47-52 (2006
39. Wong Y.H., et al. KinasePhos 2.0: a web server for identifying protein kinase-specific phosphorylation sites based on sequences and coupling patterns. Nucleic Acids Res. 35, W588-W594 (2007
40. Wang W., et al. PTPN14 is required for the density-dependent control of YAP1. Genes Dev. 26, 1959-1971 (2012
41. Welcker, M., & Clurman, B.E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 8, 83-93 (2008
42. King B., et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 153, 1552-1566 (2013
43. Zhang, H., Pasolli, H.A., & Fuchs, E. Yes-Associated protein (YAP) transcriptional coactivator functions in balancing growth and differentiation in skin. Proc. Natl. Acad. Sci. USA 108, 2270-2275 (2011
44. Schlegelmilch K., et al. Yap1 acts downstream of a-catenin to control epidermal proliferation. Cell 144, 782-795 (2011
45. Wilson K.E., et al. PTPN14 forms a complex with Kibra and LATS1 proteins and negatively regulates the YAP oncogenic function. J. Biol. Chem. 289, 23693-23700 (2014
46. Hao, Y., Chun, A., Cheung, K., Rashidi, B., & Yang, X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J. Biol. Chem. 283, 5496-5509 (2008
47. Tate, G., Kishimoto, K., & Mitsuya, T. Biallelic alterations of the large tumor suppressor 1 (LATS1) gene in infiltrative, but not superficial, basal cell carcinomas in a Japanese patient with nevoid basal cell carcinoma syndrome. Med. Mol. Morphol. 48, 177-182 (2015
48. Krauthammer M., et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014 (2012
49. Hammond D., et al. Melanoma-Associated mutations in protein phosphatase 6 cause chromosome instability and DNA damage owing to dysregulated Aurora-A. J. Cell Sci. 126, 3429-3440 (2013
50. Duman-Scheel, M., Weng, L., Xin, S., & Du, W. Hedgehog regulates cell growth and proliferation by inducing cyclin D and cyclin E. Nature 417, 299-304 (2002
51. Stefansson, B., & Brautigan, D.L. Protein phosphatase PP6 N terminal domain restricts G1 to S phase progression in human cancer cells. Cell Cycle 6, 1386-1392 (2007
52. Couzens A.L., et al. Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions. Sci. Signal. 6, rs15 (2013
53. Jaju P.D., et al. Mutations in the kinetochore gene KNSTRN in basal cell carcinoma. J. Invest. Dermatol. 135, 3197-3200 (2015
54. Lee C.S., et al. Recurrent point mutations in the kinetochore gene KNSTRN in cutaneous squamous cell carcinoma. Nat. Genet. 46, 1060-1062 (2014
55. Santos, G.C., Zielenska, M., Prasad, M., & Squire, J.A. Chromosome 6p amplification and cancer progression. J. Clin. Pathol. 60, 1-7 (2007
56. Zhang H., et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J. Biol. Chem. 284, 13355-13362 (2009
57. Valentijn L.J., et al. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc. Natl. Acad. Sci. USA 109, 19190-19195 (2012
58. Pfister S., et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J. Clin. Oncol. 27, 1627-1636 (2009
59. Xu L., et al. Sonic Hedgehog pathway is essential for neuroblastoma cell proliferation and tumor growth. Mol. Cell. Biochem. 364, 235-241 (2012
60. Oue, T., Yoneda, A., Uehara, S., Yamanaka, H., & Fukuzawa, M. Increased expression of the hedgehog signaling pathway in pediatric solid malignancies. J. Pediatr. Surg. 45, 387-392 (2010
61. Murphy, A.J., et al. Aberrant activation, nuclear localization, and phosphorylation of Yes-Associated protein-1 in the embryonic kidney and Wilms tumor. Pediatr. Blood Cancer 61, 198-205 (2014
62. Pugh T.J., et al. The genetic landscape of high-risk neuroblastoma. Nat. Genet. 45, 279-284 (2013
63. Ellison, D.W., et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 121, 381-396 (2011
64. Williams R.D., et al. Multiple mechanisms of MYCN dysregulation in Wilms tumour. Oncotarget 6, 7232-7243 (2015
65. Nikolaev S.I., et al. Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations. Nat. Commun. 5, 4654 (2014
66. Vogelstein B., et al. Cancer genome landscapes. Science 339, 1546-1558 (2013
67. Li, H., & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009
68. McKenna A., et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010
69. Cibulskis K., et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013
70. Nikolaev S., et al. Extrachromosomal driver mutations in glioblastoma and low-grade glioma. Nat. Commun. 5, 5690 (2014
71. Mermel C.H., et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011
72. Lawrence M.S., et al. Mutational heterogeneity in cancer and the search for new cancer-Associated genes. Nature 499, 214-218 (2013
73. Roadmap Epigenomics Consortium. Integrative analysis of 111 reference human epigenomes. Nature 518 317-330 (2015
74. Chen C.L., et al. Impact of replication timing on non-CpG and CpG substitution rates in mammalian genomes. Genome Res. 20, 447-457 (2010
75. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517 576-582 (2015
76. Nikolayeva, O., & Robinson, M.D. edgeR for differential RNA-seq and ChIP-seq analysis: an application to stem cell biology. Methods Mol. Biol. 1150, 45-79 (2014
77. Huang, W., Sherman, B.T., & Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009
78. Huang, W., Sherman, B.T., & Lempicki, R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1-13 (2009
79. Subramanian A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005
80. Buchan, D.W., Minneci, F., Nugent, T.C., Bryson, K., & Jones, D.T. Scalable web services for the PSIPRED Protein Analysis Workbench. Nucleic Acids Res. 41, W349-W357 (2013
81. Dinkel H., et al. The eukaryotic linear motif resource ELM: 10 years and counting. Nucleic Acids Res. 42, D259-D266 (2014
82. Eswar N., et al. Comparative protein structure modeling using MODELLER. Curr. Protoc. Protein Sci. Chapter 2, Unit 2.9 (2007
83. Guerois, R., Nielsen, J.E., & Serrano, L. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J. Mol. Biol. 320, 369-387 (2002
84. Lodrini M., et al. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Res. 41, 6018-6033 (2013
85. Xiao W., et al. Mutual interaction between YAP and c-Myc is critical for carcinogenesis in liver cancer. Biochem. Biophys. Res. Commun. 439, 167-172 (2013
86. Li L., et al. MEK1 promotes YAP and their interaction is critical for tumorigenesis in liver cancer. FEBS Lett. 587, 3921-3927 (2013
87. Gerdes, J., Becker, M.H., Key, G., & Cattoretti, G. Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J. Pathol. 168, 85-86 (1992